EUVIMEDEUVIMED entdecken
Crossref

In Brief: Apixaban vs Rivaroxaban for Acute VTE

The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 103-103

DOI: 10.58347/tml.2026.1757f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban (Xarelto, and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at least 3 months.1 The other DOACs (edoxaban [Savaysa] and dabigatran [Pradaxa, and generics]) are alternatives for long-term treatment, but they require prior treatment with low-molecular-weight heparin for ≥5 days.2 Until recently, no large randomized trial directly comparing the safety of apixaban and rivaroxaban for treatment of VTE was available.

Schlagwörter

Stichwörter der Autor:innen

DOACPradaxaSavaysaadverse effectsapixabandabigatranedoxabanrivaroxabansafetyvenous thromboembolism

Zitieren

APA

(2026). In Brief: Apixaban vs Rivaroxaban for Acute VTE. The Medical Letter on Drugs and Therapeutics, 68(1757), 103-103. https://doi.org/10.58347/tml.2026.1757f

Vancouver

In Brief: Apixaban vs Rivaroxaban for Acute VTE. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):103-103. doi:10.58347/tml.2026.1757f

BibTeX
@article{euvimed2026,
  title = {In Brief: Apixaban vs Rivaroxaban for Acute VTE},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1757},
  pages = {103--103},
  doi = {10.58347/tml.2026.1757f}
}
Kostenlos starten →